{"id":"https://openalex.org/W4361930601","doi":"https://doi.org/10.1158/1078-0432.22467524.v1","title":"Supplemental Figure 3B from Exposure\u2013Response of Veliparib to Inform Phase II Trial Design in Refractory or Relapsed Patients with Hematological Malignancies","display_name":"Supplemental Figure 3B from Exposure\u2013Response of Veliparib to Inform Phase II Trial Design in Refractory or Relapsed Patients with Hematological Malignancies","publication_year":2023,"publication_date":"2023-03-31","ids":{"openalex":"https://openalex.org/W4361930601","doi":"https://doi.org/10.1158/1078-0432.22467524.v1"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.22467524.v1","doi":"https://doi.org/10.1158/1078-0432.22467524.v1","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.22467524.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"supplementary-materials","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"http://dx.doi.org/10.1158/1078-0432.22467524.v1","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5052331821","display_name":"Shailly Mehrotra","orcid":"https://orcid.org/0009-0007-0047-538X","observed_orcids":["https://orcid.org/0009-0007-0047-538X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Shailly Mehrotra","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050047645","display_name":"Mathangi Gopalakrishnan","orcid":"https://orcid.org/0000-0003-2881-9870","observed_orcids":["https://orcid.org/0000-0003-2881-9870"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mathangi Gopalakrishnan","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083885025","display_name":"Jogarao V. S. Gobburu","orcid":"https://orcid.org/0000-0002-8348-4295","observed_orcids":["https://orcid.org/0000-0002-8348-4295"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jogarao Gobburu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020575293","display_name":"Jiuping Jay Ji","orcid":"https://orcid.org/0000-0002-5287-6157","observed_orcids":["https://orcid.org/0000-0002-5287-6157"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jiuping Ji","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079274832","display_name":"Jacqueline M. Greer","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jacqueline M. Greer","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046042179","display_name":"Richard Piekarz","orcid":"https://orcid.org/0000-0002-3591-7893","observed_orcids":["https://orcid.org/0000-0002-3591-7893"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Richard Piekarz","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040758762","display_name":"Judith E. Karp","orcid":"https://orcid.org/0000-0003-4754-127X","observed_orcids":["https://orcid.org/0000-0003-4754-127X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Judith E. Karp","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045709974","display_name":"Keith William Pratz","orcid":"https://orcid.org/0000-0002-1284-8266","observed_orcids":["https://orcid.org/0000-0002-1284-8266"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Keith W. Pratz","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5015341987","display_name":"Michelle A. Rudek","orcid":"https://orcid.org/0000-0001-5739-6868","observed_orcids":["https://orcid.org/0000-0001-5739-6868"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Michelle A. Rudek","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/veliparib","display_name":"veliparib","score":1.0},{"id":"https://openalex.org/keywords/parp-inhibitors","display_name":"PARP inhibitors","score":0.7839999794960022},{"id":"https://openalex.org/keywords/peripheral-blood-mononuclear-cells","display_name":"peripheral blood mononuclear cells","score":0.800000011920929},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.9010000228881836},{"id":"https://openalex.org/keywords/phase-ii-trial-design","display_name":"phase II trial design","score":0.9259999990463257}],"concepts":[{"id":"https://openalex.org/C2781312401","wikidata":"https://www.wikidata.org/wiki/Q7919041","display_name":"Veliparib","level":5,"score":0.8992990851402283},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6140803098678589},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.5679972171783447},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5540324449539185},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5196148753166199},{"id":"https://openalex.org/C3019096185","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Complete response","level":3,"score":0.45074230432510376},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.14963921904563904},{"id":"https://openalex.org/C182979987","wikidata":"https://www.wikidata.org/wiki/Q3907241","display_name":"Poly ADP ribose polymerase","level":4,"score":0.13702529668807983},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.09903749823570251},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.07539254426956177},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C82381507","wikidata":"https://www.wikidata.org/wiki/Q416878","display_name":"Polymerase","level":3,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1078-0432.22467524.v1","doi":"https://doi.org/10.1158/1078-0432.22467524.v1","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.22467524.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.22467524.v1","doi":"https://doi.org/10.1158/1078-0432.22467524.v1","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.22467524.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9537000060081482}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2741379995","https://openalex.org/W4361959679","https://openalex.org/W2584631269","https://openalex.org/W2970540816","https://openalex.org/W2795578649","https://openalex.org/W2901175244","https://openalex.org/W2615994354","https://openalex.org/W3207103941","https://openalex.org/W4361818717","https://openalex.org/W2521377778"],"abstract_inverted_index":{"Relationship":[0],"between":[1],"veliparib":[2],"exposure-%":[3],"CFB":[4],"in":[5,8,13],"PAR":[6,14],"levels":[7],"PBMC":[9],"(A)":[10],"and":[11],"\ufffdB":[12],"levels-ORR":[15],"(B)":[16]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2023-04-05T00:00:00"}